Literature DB >> 22609570

Insulin-like growth factor 1 (IGF1) and its active peptide (1-3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms.

Aiden P Corvin1, Ines Molinos, Graham Little, Gary Donohoe, Michael Gill, Derek W Morris, Daniela Tropea.   

Abstract

Insulin-like growth factor-1 (IGF1) and its active peptide (1-3)IGF1 modulate brain growth and plasticity and are candidate molecules for treatment of brain disorders. IGF1 N-terminal portion is naturally cleaved to generate the tri-peptide (1-3)IGF1 (glycine-praline-glutamate). IGF1 and (1-3)IGF have been proposed as treatment for neuropathologies, yet their effect on nerve cells has not been directly compared. In this study we examine the effects of IGF1 and (1-3)IGF1 in primary cortical cultures and measure the expression levels of markers for intracellular pathways and synaptic function. We find that both treatments activate the IGF1 receptor and enhance the expression of synaptic markers, however, they activate different intracellular pathways. Furthermore, (1-3)IGF1 administration increases the expression of endogenous IGF1, suggesting a direct interaction between the two molecules. The results show that the two molecules increase the expression of synaptic proteins through activating different cellular mechanisms.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609570     DOI: 10.1016/j.neulet.2012.05.029

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

Review 1.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

2.  Pregnancy-Associated Plasma Protein-aa Regulates Photoreceptor Synaptic Development to Mediate Visually Guided Behavior.

Authors:  Andrew H Miller; Hollis B Howe; Bryan M Krause; Scott A Friedle; Matthew I Banks; Brian D Perkins; Marc A Wolman
Journal:  J Neurosci       Date:  2018-05-08       Impact factor: 6.167

Review 3.  Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

Authors:  Jesse L Costales; Alexander Kolevzon
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

4.  Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale.

Authors:  Jeffrey L Neul; Daniel G Glaze; Alan K Percy; Tim Feyma; Arthur Beisang; Thuy Dinh; Bernhard Suter; Evdokia Anagnostou; Mike Snape; Joseph Horrigan; Nancy E Jones
Journal:  J Child Neurol       Date:  2015-04-20       Impact factor: 1.987

Review 5.  Rett Syndrome: Reaching for Clinical Trials.

Authors:  Lucas Pozzo-Miller; Sandipan Pati; Alan K Percy
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

6.  NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome.

Authors:  Robert M J Deacon; Larry Glass; Mike Snape; Michael J Hurley; Francisco J Altimiras; Rodolfo R Biekofsky; Patricia Cogram
Journal:  Neuromolecular Med       Date:  2015-01-23       Impact factor: 3.843

7.  Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function.

Authors:  Meagan R Pitcher; Christopher S Ward; E Melissa Arvide; Christopher A Chapleau; Lucas Pozzo-Miller; Andreas Hoeflich; Manaswini Sivaramakrishnan; Stefanie Saenger; Friedrich Metzger; Jeffrey L Neul
Journal:  Hum Mol Genet       Date:  2013-03-05       Impact factor: 6.150

Review 8.  WONOEP appraisal: Molecular and cellular biomarkers for epilepsy.

Authors:  Lauren E Walker; Damir Janigro; Uwe Heinemann; Raili Riikonen; Christophe Bernard; Manisha Patel
Journal:  Epilepsia       Date:  2016-07-04       Impact factor: 5.864

9.  Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.

Authors:  Omar S Khwaja; Eugenia Ho; Katherine V Barnes; Heather M O'Leary; Luis M Pereira; Yaron Finkelstein; Charles A Nelson; Vanessa Vogel-Farley; Geneva DeGregorio; Ingrid A Holm; Umakanth Khatwa; Kush Kapur; Mark E Alexander; Deirdre M Finnegan; Nicole G Cantwell; Alexandra C Walco; Leonard Rappaport; Matt Gregas; Raina N Fichorova; Michael W Shannon; Mriganka Sur; Walter E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-12       Impact factor: 11.205

10.  Long-term fluoxetine treatment induces input-specific LTP and LTD impairment and structural plasticity in the CA1 hippocampal subfield.

Authors:  Francisco J Rubio; Estíbaliz Ampuero; Rodrigo Sandoval; Jorge Toledo; Floria Pancetti; Ursula Wyneken
Journal:  Front Cell Neurosci       Date:  2013-05-09       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.